Formic Acid

Formic Acid

SCHEMBL3537417

Cc1ccc(C2CCc3nc(NC(=N)N)sc3C2)cc1.O=CO

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.42
MAPT P10636 8/20 0.42
MAPK1 P28482 3/20 0.42
POLB P06746 2/20 0.42
HTT P42858 2/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
NPC1 O15118 6/20 0.41
RAB9A P51151 5/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
ALDH1A1 P00352 8/20 0.39
TP53 P04637 4/20 0.39
TDP1 Q9NUW8 2/20 0.38
THRB P10828 1/20 0.38
SLC27A1 Q6PCB7 1/20 0.38
KDM4E B2RXH2 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
ALOX12 P18054 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3534984 0.95 LMNA (0.46) LMNAMAPTMAPK1POLBHTT
SCHEMBL13314851 0.95 LMNA (0.46) LMNAMAPTMAPK1POLBHTT
Formic Acid SCHEMBL3535992 0.90 MAPT (0.47) LMNAMAPTMAPK1POLBHTT
Formic Acid SCHEMBL3539149 0.88 MAPT (0.43) LMNAMAPTMAPK1POLBHTT
Formic Acid SCHEMBL3534517 0.87 ROCK2 (0.42) LMNAMAPTMAPK1POLBHTT
Formic Acid SCHEMBL3533664 0.85 MAPT (0.45) LMNAMAPTMAPK1TSHRNPC1
Formic Acid SCHEMBL3542530 0.84 MAPT (0.41) LMNAMAPTMAPK1POLBHTT
SCHEMBL13314834 0.84 MAPT (0.46) LMNAMAPTMAPK1POLBHTT
SCHEMBL3536144 0.84 MAPT (0.46) LMNAMAPTMAPK1POLBHTT
SCHEMBL3541679 0.84 MAPT (0.48) LMNAMAPTMAPK1POLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727979-B2 Guanidine derivatives and their use as neuropeptide FF receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2010-06-01 US disclosed
US-20060194788-A1 Guanidine derivatives and their use as neuropeptide ff receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194788-A1 Guanidine derivatives and their use as neuropeptide ff receptor antagonists NPFFR1, OGFR, NPFFR2 LMNA 2988/4885MAPT 1891/4885MAPK1 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.